Key Highlights
- BDMD traded near $1.12 at last closing, valuing the company at roughly $47 million.
- First-half 2026 Revenue grew about 25% with a swing to positive net income, following a 2025 revenue decline of about 39%.
- The company relocated its global headquarters to New York City in June 2026 and named Mark Saxton as U.S. chief executive.
- Baird Medical secured product registrations in Pakistan and regulatory clearance in Argentina during 2026.
Baird Medical Investment Holdings Limited (NASDAQ:BDMD) has spent 2026 rebuilding its story around the United States, and the market is beginning to take note. The Nasdaq-listed maker of microwave ablation devices, trading under the ticker BDMD, relocated its global headquarters to New York, installed a U.S. chief executive and reported a return to profitability at the half-year mark. After a difficult 2025, those steps have put the small-cap medical-device name back on some September 2026 watchlists.
Company and Latest Development
Baird Medical develops microwave ablation (MWA) systems used to treat benign and malignant tumors, with its BD-GT platform at the center of a growing international footprint. The company became publicly traded through a 2024 Business combination with ExcelFin Acquisition Corp and reports to the SEC as a foreign private issuer, filing annual results on Form 20-F. Its most recent milestone came at the half-year: for the six months ended June 30, 2026, Baird Medical reported roughly 25% revenue growth and a swing to positive net income, driven in part by early traction in the U.S. market. That followed a full-year 2025 in which revenue fell to about $22.5 million, down roughly 39% year over year, alongside a sizable operating loss.
What Is Driving Attention Around BDMD?
The renewed interest ties to a clear strategic pivot toward America. In June 2026 the company moved its global headquarters to New York City, and it appointed Mark Saxton as U.S. chief executive to lead commercial expansion, having also established North American production capacity. Baird Medical has widened its geographic reach as well, securing product registrations in Pakistan, regulatory clearance in Argentina, and completing first procedures in Vietnam and Argentina, while running clinical Training in Indonesia. It has also signed cooperation agreements, including with Alpmed on irreversible electroporation technology, and launched AI-assisted surgical software registered in the U.S. EU and China. The modest single-session move reflected at last closing does not trace to one confirmed catalyst; the broader narrative is the turn toward profitability and U.S. growth.
Key Numbers and Company Position
Verified figures include full-year 2025 revenue of about $22.5 million with a gross Margin near 84% and an operating loss of roughly $25.6 million. The half-year 2026 report showed approximately 25% revenue growth and positive net income. Recent market data put the shares near $1.12 with a market Capitalization of roughly $47 million, keeping Baird Medical firmly in micro-cap territory. As a 20-F filer, the company's detailed disclosures arrive on a foreign-issuer schedule rather than through U.S. quarterly 10-Qs.
What Could Come Next?
Investors may be watching whether the U.S. commercial build-out translates into sustained revenue growth and durable profitability in the second half of 2026. Additional regulatory registrations across new markets, progress on the electroporation and AI-software initiatives, and any updates to production capacity could serve as catalysts. The next scheduled financial disclosure and any 6-K updates on international clearances remain key items to monitor.
Risks to Watch
As a micro-cap medical-device company with operations spanning multiple countries, Baird Medical faces execution risk in scaling U.S. sales, currency and cross-border regulatory complexity, and competition from larger ablation and oncology-device players. The steep 2025 revenue decline underscores how quickly results can swing. Thin trading Liquidity can amplify share-price volatility, and future financing needs could pressure the stock. Foreign-private-issuer reporting also means less frequent quarterly detail than domestic peers.
A U.S.-Focused Reset After a Difficult 2025
Baird Medical enters the closing months of 2026 with a sharper U.S. focus, a new headquarters, fresh Leadership and a half-year return to profit. Whether the strategic reset holds will depend on execution across its expanding international markets and its ability to convert product registrations into revenue.






Please wait processing your request...